Medical Oncology

Targeted therapies

Questions discussed in this category

Under what circumstances, if any, would you wait on initiating a TKI for metastatic recurrence of a Stage III NSCLC which occurred while on consolidative durvalumab to minimize pneumonitis risk?

One particular circumstance involved detecting a ROS1 fusion upon the metastatic recurrence. Is this pneumonitis risk seen with osimertinib alon...

2 Answers available

Do you consider using 160 mg osimertinib in patients with EGFR-positive metastatic NSCLC to the brain?

1 Answer available

How do you manage a patient with metastatic NSCLC whose initial mutation testing was limited or results are no longer available?

How do you operationalize finding biomarker information in EHRs/testing portals, either for your own patients or if they have changed providers? If a...

4 Answers available

What are your treatment considerations for a patient with stage IVb NSCLC who is KRAS G12C mutated and PD-L1 high (>50%)?

3 Answers available

How do you approach treatment sequencing in KRAS G12C NSCLC?

Is there evidence or experience to support use of targeted therapy for KRAS G12C mutated NSCLC as first line in place of chemotherapy?

3 Answers available

Are there best practices for managing or mitigating toxicity from sotorasib such as hyperbilirubinemia or edema?

3 Answers available

What data do you view as most impactful to treatment decisions in 1L metastatic ccRCC?

How do you weigh the various efficacy endpoints in the trials of novel combinations in ccRCC? Are there specific clinical populations that you ...

3 Answers available

In stage II/III node positive patients with driver mutations positive NSCLC who are not surgical candidates and are unlikely to tolerate concurrent chemotherapy and radiation, would you consider radiation alone, TKI alone, or would you ever consider TKI + RT?

What would be the treatment duration if using oral TKI?

1 Answer available

How do you approach patients with driver mutation positive, Stage IV NSCLC who don't benefit from upfront first-line TKI?

Although a small subset, do you generally move these patients directly on to chemotherapy +/- immunotherapy or does it depend on the specific mutation...

1 Answer available

Should 3 years of adjuvant osimertinib be the standard of care for resected Stage IB-IIIA EGFRm NSCLC?

6 Answers available

How do you approach a patient who responded to first line osimertinib but develop an isolated progressing lesion that retains sensitizing EGFR mutation but develops MET amplification?

Would you continue osimertinib after radiation therapy, switch to crizotinib, or consider chemotherapy +/- immunotherapy?

1 Answer available